Nxera Pharma and Cancer Research UK have announced the first patient has been dosed in a phase 2a trial of HTL0039732, an ...

Among patients with HS, HiSCR75, HiSCR90 and HiSCR100 responses seen at one year were sustained and improved to three years ...

The MHRA has approved vorasidenib (Voranigo) for patients aged 12 and above with grade 2 astrocytoma or oligodendroglioma ...

AstraZeneca’s Imfinzi (durvalumab) has been approved for NHS use in England and Wales for adults with limited-stage small ...

Arcinova, a Quotient Sciences company and UK-based contract research development and manufacturing organisation (CRDMO), has ...

Dr Deepika Jalota, Chief Development Officer, said: “These phase 2 PYNNACLE interim trial data illustrate that rezatapopt, a ...

Lundbeck has presented new clinical data on eptinezumab at the 2025 International Headache Congress in São Paulo, ...

Thierry Van Nieuwenhove, CEO at Quotient Sciences, said: “This is a pivotal moment for RNA drug development. The combined ...

Merck has announced positive phase 3 results for Capvaxive, its 21-valent pneumococcal conjugate vaccine, in children and ...

SOM Biotech has received a positive opinion from the European Medicines Agency’s Committee for Orphan Medical Products for SOM3355, a candidate therapy for Huntington’s disease (HD). The molecule ...

Bluejay Therapeutics has enrolled the first patient in AZURE-2, a global phase 3 clinical trial evaluating brelovitug ...

Eisai has presented new clinical data for its investigational orexin 2 receptor agonist E2086 at the World Sleep 2025 ...